Carolyn K Pan, MD
Ophthalmology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 24
- 5 carriers
- Office
- 1
Offices
1 location · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
24 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Pan’s office at (408) 885-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
24 of 24 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A116645 · Current
Licensed to practise in California · since 2011 · expires 2028-06-30 · Wayne State University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$39,429
Medicare paid this office $39,429 for 138 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection of drug into eye | 71 | $19,569 | $91 |
| Imaging of retina | 132 | $6,660 | $21 |
| Destruction of leaking blood vessels of retina using laser | 11 | $4,033 | $288 |
| Established patient problem focused exam of visual system | 48 | $2,602 | $43 |
| Short return visit (20+ min) | 32 | $1,955 | $53 |
See all 7 services
| Injection of drug into eye | 71 | $19,569 | $91 |
| Imaging of retina | 132 | $6,660 | $21 |
| Destruction of leaking blood vessels of retina using laser | 11 | $4,033 | $288 |
| Established patient problem focused exam of visual system | 48 | $2,602 | $43 |
| Short return visit (20+ min) | 32 | $1,955 | $53 |
| Return visit (30+ min) | 16 | $1,417 | $79 |
| Photography of the retina | 13 | $268 | $18 |
Procedures Medicare counted
| Cataract surgery | 1-10 | None |
Who their Medicare patients are
138 Original Medicare patients in 2024. Average age 71 · Under 65 23% · 85 and older 11% · Women 56% · Also on Medicaid 81% · Health risk score 2.79. Sicker patients than 9 in 10 peers; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Diabetes 74% · Chronic kidney disease 47% · Heart failure 27% · Coronary heart disease 25% · Depression 16% · Atrial fibrillation 14% · Stroke 12%.
The office billed $552,523, Medicare allowed $53,252 and paid $39,429; for 699 services of 17 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 138 | 699 | 71 | 2.79 | $552,523 | $39,429 |
| 2023 | 165 | 735 | 71 | 2.64 | $581,226 | $41,821 |
| 2022 | 158 | 562 | 71 | 2.39 | $428,349 | $29,601 |
| 2021 | 145 | 562 | 69 | 2.22 | $468,950 | $36,639 |
| 2020 | 165 | 548 | 69 | 2.56 | $431,125 | $34,063 |
| 2019 | 203 | 689 | 68 | 2.26 | $543,465 | $51,247 |
| 2018 | 179 | 592 | 67 | 2.29 | $390,391 | $43,127 |
| 2017 | 114 | 286 | 67 | 2.20 | $221,628 | $27,298 |
| 2016 | 212 | 659 | 67 | 2.44 | $525,874 | $50,107 |
| 2015 | 183 | 420 | 69 | 2.17 | $451,761 | $45,140 |
| 2014 | 260 | 682 | 68 | 1.96 | $656,713 | $75,353 |
| 2013 | 152 | 258 | 73 | 1.94 | $233,392 | $26,186 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Injection of drug into eye | 64 | $17,101 | $94 |
| Imaging of retina | 156 | $6,994 | $21 |
| Return visit (30+ min) | 41 | $3,255 | $76 |
| Short return visit (20+ min) | 48 | $3,193 | $52 |
| Established patient problem focused exam of visual system | 37 | $1,537 | $38 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 12 | $431 | $36 |
| Photography of the retina | 20 | $383 | $16 |
2022: 7 services
| Injection of drug into eye | 46 | $10,454 | $84 |
| Imaging of retina | 143 | $5,055 | $21 |
| Return visit (30+ min) | 32 | $2,822 | $78 |
| Short return visit (20+ min) | 39 | $2,401 | $51 |
| Established patient problem focused exam of visual system | 29 | $1,452 | $43 |
| Photography of the retina | 18 | $420 | $18 |
| Exam of visual field with extended testing | 19 | $411 | $21 |
2021: 6 services
| Injection of drug into eye | 43 | $8,600 | $85 |
| Imaging of retina | 140 | $5,257 | $21 |
| Short return visit (20+ min) | 42 | $2,780 | $51 |
| Return visit (30+ min) | 21 | $1,906 | $87 |
| Established patient problem focused exam of visual system | 28 | $1,632 | $44 |
| Established patient complete exam of visual system | 19 | $964 | $51 |
2020: 5 services
| Injection of drug into eye | 37 | $8,493 | $90 |
| Return visit (30+ min) | 85 | $5,407 | $50 |
| Imaging of retina | 142 | $4,540 | $20 |
| Established patient problem focused exam of visual system | 30 | $1,551 | $39 |
| Short return visit (20+ min) | 15 | $660 | $41 |
2019: 7 services
| Injection of drug into eye | 45 | $10,332 | $83 |
| Imaging of retina | 172 | $6,144 | $22 |
| Destruction of leaking blood vessels of retina using laser | 17 | $5,585 | $279 |
| Established patient problem focused exam of visual system | 103 | $5,535 | $41 |
| Return visit (30+ min) | 35 | $2,328 | $63 |
| Exam of visual field with extended testing | 19 | $506 | $25 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 12 | $502 | $42 |
2018: 5 services
| Injection of drug into eye | 36 | $8,948 | $89 |
| Return visit (30+ min) | 83 | $7,231 | $58 |
| Imaging of retina | 131 | $4,780 | $22 |
| Established patient problem focused exam of visual system | 37 | $1,821 | $44 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 22 | $883 | $40 |
2017: 5 services
| Injection of drug into eye | 17 | $3,340 | $93 |
| Return visit (30+ min) | 44 | $3,325 | $64 |
| Imaging of retina | 70 | $2,126 | $23 |
| Short return visit (20+ min) | 34 | $1,599 | $42 |
| Imaging of optic nerve | 11 | $232 | $21 |
2016: 9 services
| Injection of drug into eye | 34 | $8,202 | $85 |
| Imaging of retina | 167 | $5,427 | $22 |
| Short return visit (20+ min) | 84 | $4,277 | $41 |
| Destruction of leaking blood vessels of retina using laser | 11 | $3,694 | $284 |
| Established patient complete exam of visual system | 43 | $2,627 | $54 |
| Established patient problem focused exam of visual system | 31 | $1,390 | $37 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 21 | $822 | $39 |
| Photography of the retina | 22 | $436 | $20 |
| Exam of visual field with extended testing | 15 | $382 | $24 |
2015: 7 services
| Destruction of leaking blood vessels of retina using laser | 16 | $19,059 | $908 |
| Established patient complete exam of visual system | 85 | $6,505 | $65 |
| Injection of drug into eye | 24 | $4,535 | $84 |
| Imaging of retina | 134 | $4,010 | $23 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 14 | $564 | $40 |
| Photography of the retina | 15 | $328 | $22 |
| Exam of visual field with extended testing | 12 | $281 | $23 |
2014: 8 services
| Established patient complete exam of visual system | 136 | $11,777 | $64 |
| Removal of cataract with insertion of prosthetic lens | 15 | $9,221 | $615 |
| Injection of drug into eye | 28 | $6,637 | $93 |
| Imaging of retina | 170 | $6,495 | $25 |
| Established patient problem focused exam of visual system | 29 | $1,312 | $42 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 25 | $1,092 | $44 |
| Photography of the retina | 24 | $519 | $22 |
| Exam of visual field with extended testing | 13 | $340 | $26 |
2013: 6 services
| Injection of drug into eye | 41 | $4,535 | $89 |
| Established patient problem focused exam of visual system | 45 | $3,628 | $70 |
| Established patient complete exam of visual system | 28 | $2,092 | $72 |
| Established patient problem focused exam of visual system | 37 | $1,679 | $44 |
| Unclassified biologics | 14 | $698 | None |
| Imaging of retina | 25 | $681 | $26 |
Medicaid work
$41,521 in 2024
Medicaid paid $41,521 for 2,635 billed services this clinician did in 2024, up to 134 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Intravitreal injection of a pharmacologic agent (separate procedure) | 670 | $31,303 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 1,259 | $3,892 |
| Aflibercept injection | 50 | $2,545 |
| Short return visit (20+ min) | 50 | $2,086 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 299 | $1,171 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 103 | $524 |
| Service | 163 | $0 |
| Injection, bevacizumab, 10 mg | 41 | $0 |
| 2024 | 2,635 | 8 | 134 | $41,521 |
| 2023 | 3,129 | 7 | 157 | $34,559 |
| 2022 | 1,523 | 6 | 101 | $24,502 |
| 2021 | 1,002 | 5 | 67 | $14,742 |
| 2020 | 1,142 | 4 | 75 | $16,146 |
| 2019 | 1,358 | 5 | 64 | $24,138 |
| 2018 | 1,285 | 4 | 71 | $33,156 |
See the largest Medicaid services in earlier years
2023
| Intravitreal injection of a pharmacologic agent (separate procedure) | 773 | $22,997 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 1,590 | $4,946 |
| Short return visit (20+ min) | 93 | $3,830 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 423 | $2,275 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 82 | $313 |
| Injection, bevacizumab, 10 mg | 38 | $135 |
| Service | 130 | $62 |
2022
| Intravitreal injection of a pharmacologic agent (separate procedure) | 399 | $17,553 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 333 | $2,977 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 749 | $2,751 |
| Short return visit (20+ min) | 14 | $595 |
| Service | 16 | $546 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 12 | $80 |
2021
| Intravitreal injection of a pharmacologic agent (separate procedure) | 310 | $11,397 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 615 | $2,155 |
| Short return visit (20+ min) | 32 | $555 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 30 | $452 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 15 | $184 |
2020
| Intravitreal injection of a pharmacologic agent (separate procedure) | 284 | $11,463 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 569 | $2,384 |
| Return visit (30+ min) | 192 | $1,593 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 97 | $706 |
2019
| Intravitreal injection of a pharmacologic agent (separate procedure) | 390 | $18,443 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 638 | $2,915 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 277 | $2,000 |
| Return visit (30+ min) | 37 | $406 |
| Short return visit | 16 | $374 |
2018
| Intravitreal injection of a pharmacologic agent (separate procedure) | 353 | $28,581 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 569 | $2,238 |
| Return visit (30+ min) | 313 | $2,119 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 50 | $218 |
Drugs they prescribed that Part D paid
$2,116
Pharmacies billed $2,116 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 108) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
95 generic and 13 brand-name prescriptions · $2,116 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Brimonidine | 25 | $319 | $13 |
| Dorzolamide-Timolol | 14 | $206 | $15 |
| Latanoprost | 26 | $187 | $7 |
| Timolol Maleate | 16 | $110 | $7 |
Year by year
| 2024 | 108 | 25 | 0% (0) | 12% | $2,116 |
| 2023 | 82 | 30 | 0% (0) | 24% | $3,494 |
| 2022 | 95 | 33 | 0% (0) | 36% | $5,250 |
| 2021 | 144 | 42 | 0% (0) | 47% | $8,496 |
| 2020 | 85 | 31 | 0% (0) | 29% | $4,701 |
| 2019 | 83 | 24 | 0% (0) | 35% | $5,082 |
| 2018 | 105 | 29 | 0% (0) | 36% | $6,118 |
| 2017 | 210 | 53 | 0% (0) | 28% | $11,510 |
| 2016 | 249 | 71 | 0% (0) | 41% | $17,058 |
| 2015 | 88 | 39 | 0% (0) | 56% | $6,451 |
| 2014 | 162 | 55 | None | None | $7,422 |
| 2013 | 144 | 73 | None | 51% | $5,893 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Prednisolone Acetate | 16 | $717 | $45 |
| Brimonidine | 11 | $331 | $30 |
| Timolol Maleate | 15 | $136 | $9 |
| Latanoprost | 14 | $129 | $9 |
2022: 3 drugs
| Prednisolone Acetate | 28 | $1,641 | $59 |
| Dorzolamide-Timolol | 11 | $350 | $32 |
| Latanoprost | 13 | $211 | $16 |
2021: 5 drugs
| Prednisolone Acetate | 48 | $2,787 | $58 |
| Dorzolamide-Timolol | 16 | $399 | $25 |
| Timolol Maleate | 12 | $246 | $20 |
| Latanoprost | 11 | $220 | $20 |
| Acyclovir | 13 | $130 | $10 |
2020: 3 drugs
| Prednisolone Acetate | 15 | $723 | $48 |
| Dorzolamide-Timolol | 11 | $364 | $33 |
| Acyclovir | 11 | $197 | $18 |
2019: 2 drugs
| Prednisolone Acetate | 15 | $638 | $43 |
| Latanoprost | 22 | $362 | $16 |
2018: 4 drugs
| Olopatadine | 13 | $980 | $75 |
| Prednisolone Acetate | 12 | $681 | $57 |
| Latanoprost | 28 | $381 | $14 |
| Timolol Maleate | 11 | $123 | $11 |
2017: 7 drugs
| Brimonidine | 21 | $2,907 | $138 |
| Prednisolone Acetate | 19 | $881 | $46 |
| Azelastine | 12 | $669 | $56 |
| Latanoprost | 51 | $638 | $13 |
| Olopatadine | 13 | $505 | $39 |
| Dorzolamide | 24 | $379 | $16 |
| Timolol Maleate | 31 | $267 | $9 |
2016: 7 drugs
| Brimonidine | 32 | $4,357 | $136 |
| Travatan Z | 12 | $3,310 | $276 |
| Prednisolone Acetate | 23 | $1,103 | $48 |
| Azelastine | 13 | $835 | $64 |
| Latanoprost | 52 | $584 | $11 |
| Dorzolamide | 25 | $384 | $15 |
| Timolol Maleate | 28 | $232 | $8 |
2015: 3 drugs
| Brimonidine | 11 | $1,075 | $98 |
| Prednisolone Acetate | 20 | $872 | $44 |
| Latanoprost | 12 | $142 | $12 |
2014: 5 drugs
| Prednisolone Acetate | 36 | $2,174 | $60 |
| Brimonidine | 18 | $1,382 | $77 |
| Dorzolamide | 21 | $733 | $35 |
| Latanoprost | 22 | $328 | $15 |
| Timolol Maleate | 18 | $217 | $12 |
2013: 4 drugs
| Vigamox | 15 | $1,510 | $101 |
| Prednisolone Acetate | 39 | $888 | $23 |
| Neomycin-Polymyxin-Dexameth | 29 | $419 | $14 |
| Atropine Sulfate | 15 | $199 | $13 |
Money from drug and device companies
$2,722 in 2025
| 2025 | 5 | 7 | $2,000 | $2,722 |
| 2024 | 4 | 6 | None | $686 |
| 2023 | 2 | 3 | None | $250 |
| 2022 | 3 | 3 | None | $311 |
| 2021 | 2 | 2 | None | $238 |
| 2019 | 4 | 6 | None | $697 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Ocular Therapeutix | None | $2,000 | 1 payment
|
| Regeneron Pharmaceuticals | Eylea Hd | $264 | 3 payments
|
| Glaukos | Photrexa Viscous and Photrexa | $177 | 1 payment
|
| Alcon Vision | Unity | $140 | 1 payment
|
| Abbvie | Ozurdex | $140 | 1 payment
|
See all 7 published payments
| Regeneron Pharmaceuticals | Meals · 2025-12-04 | Eylea Hd | $75 |
| Alcon Vision | Meals · 2025-09-12 | Unity | $140 |
| Regeneron Pharmaceuticals | Meals · 2025-09-10 | Eylea Hd | $150 |
| Regeneron Pharmaceuticals | Meals · 2025-03-20 | Eylea Hd | $39 |
| Ocular Therapeutix | Consulting · 2025-03-20 | None | $2,000 |
| Abbvie | Meals · 2025-03-19 | Ozurdex | $140 |
| Glaukos | Meals · 2025-03-11 | Photrexa Viscous and Photrexa | $177 |
See earlier years (2024, 2023, 2022, 2021, 2019)
2024: $686
| Regeneron Pharmaceuticals | Eylea Hd | $237 | 2 payments
|
| Amgen | Tepezza | $217 | 2 payments
|
| Alcon Vision | Constellation | $130 | 1 payment
|
| Tarsus Pharmaceuticals | Xdemvy | $102 | 1 payment
|
2023: $250
| Astellas Pharma US | None | $224 | 2 payments
|
| Bausch & Lomb Americas | Vyzulta | $25 | 1 payment
|
2022: $311
| Dutch Ophthalmic USA | Eva, Combined Machine | $149 | 1 payment
|
| Genentech | Vabysmo | $94 | 1 payment
|
| Regeneron Pharmaceuticals | Eylea | $67 | 1 payment
|
2021: $238
| Regeneron Healthcare Solutions | Eylea | $125 | 1 payment
|
| New World Medical | Ahmed Glaucoma Valve | $113 | 1 payment
|
2019: $697
| Genentech | Lucentis | $278 | 3 payments
|
| Genentech USA | None | $172 | 1 payment
|
| Alimera Sciences | Iluvien | $125 | 1 payment
|
| Novartis Pharmaceuticals | None | $122 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Regeneron Pharmaceuticals, Inc. · Eylea Clinical Development Program · 2021 | This clinician | $7,961 |
| Regeneron Pharmaceuticals, Inc. · A Double- Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of Vegf Trap-Eye in Patients With Diabetic Macular Edema · 2021 | This clinician | $1,844 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1083803621
- Licence
- CA A116645California A116645: Current · expires 2028-06-30
- Trained
- Wayne State University School of Medicine, 2007
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 0A1166450
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-10-19
- NPI last updated
- 2016-10-19
This is when the NPI record was last certified, not a medical board exam.